Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 110, Issue 10, Pages 2472-2478
Publisher
Springer Nature
Online
2014-04-16
DOI
10.1038/bjc.2014.204
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- (2013) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
- (2011) Carlo Buonerba et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea
- (2010) Jae-Lyun Lee et al. Cancer Research and Treatment
- Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
- (2009) Y. Loriot et al. ANNALS OF ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
- (2008) Mari Nakabayashi et al. BJU INTERNATIONAL
- Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma
- (2008) Marta Santisteban et al. Clinical & Translational Oncology
- Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
- (2008) H. Choy et al. CLINICAL CANCER RESEARCH
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
- (2007) Robert W. Ross et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now